Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.

[1]  Robin L. Jones,et al.  Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Blay,et al.  Gastrointestinal stromal tumours , 2009 .

[3]  C. Serrano,et al.  Liquid Biopsy in Gastrointestinal Stromal Tumors: Ready for Prime Time? , 2021, Current Treatment Options in Oncology.

[4]  J. Fletcher,et al.  Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain. , 2020, Cancer Discovery.

[5]  Robin L. Jones,et al.  Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. , 2020, The Lancet. Oncology.

[6]  S. George,et al.  Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade , 2020, Clinical Cancer Research.

[7]  Robin L. Jones,et al.  Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2020, The Lancet. Oncology.

[8]  J. Trent,et al.  Utility of Circulating Tumor DNA in the Management of Patients With GI Stromal Tumor: Analysis of 243 Patients. , 2020, JCO precision oncology.

[9]  J. Fletcher,et al.  Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors , 2020, BMC Cancer.

[10]  J. Trent,et al.  Identification of Genetic Alterations by Circulating Tumor DNA in Leiomyosarcoma: A Molecular Analysis of 73 Patients. , 2019, Journal of immunotherapy and precision oncology.

[11]  J. Fletcher,et al.  Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours , 2019, British Journal of Cancer.

[12]  M. Speicher,et al.  Current and future perspectives of liquid biopsies in genomics-driven oncology , 2018, Nature Reviews Genetics.

[13]  A. Gardino,et al.  A precision therapy against cancers driven by KIT/PDGFRA mutations , 2017, Science Translational Medicine.

[14]  Jing Sun,et al.  Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types , 2017, Scientific Reports.

[15]  J. Blay,et al.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[16]  C. Antonescu,et al.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Fletcher,et al.  Heterogeneity of kinase inhibitor resistance mechanisms in GIST , 2008, The Journal of pathology.

[18]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[19]  J. Fletcher,et al.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Wardelmann,et al.  Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate , 2006, Clinical Cancer Research.

[21]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[23]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[24]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.